AstraZeneca PLC continues to discuss the cause of rare blood clots with regulators and scientists after German researchers said they discovered the link to its COVID-19 vaccines.
The U.K. pharma company said the theory put forward by the Goethe University laboratory in Frankfurt on Wednesday is one of many that AstraZeneca scientists are investigating.
"We are continuing to work with regulators, recommending bodies and the scientific community around the world to understand more about the epidemiology and the possible mechanisms behind these extremely rare events,” a company spokeswoman said.